Showing 1 - 2 results of 2 for search 'Jordi Remon', query time: 0.01s Refine Results
  1. 1
    Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial

    Alectinib in combination with bevacizumab as first-line treatment in ALK-rearranged non-small cell lung cancer (ALEK-B): a single-arm, phase 2 trial by Oscar Arrieta, Luis Lara-Mejía, Eduardo Rios-Garcia, Enrique Caballé-Perez, Luis Cabrera-Miranda, Maritza Ramos-Ramírez, David Dávila-Dupont, Andrés F. Cardona, Graciela Cruz-Rico, Jordi Remon, Alexandra Garcilazo-Reyes, Rafael Rosell

    Published 2025-05-01
    Get full text
    Article
    Save to List
    Saved in:
  2. 2
    Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference

    Pushing the boundaries of radiotherapy-immunotherapy combinations: highlights from the 7th immunorad conference by Pierre-Antoine Laurent, Fabrice André, Alexandre Bobard, Desiree Deandreis, Sandra Demaria, Stephane Depil, Stefan B. Eichmüller, Cristian Fernandez-Palomo, Floris Foijer, Lorenzo Galluzzi, Jérôme Galon, Matthias Guckenberger, Kevin J. Harrington, Fernanda G. Herrera, Peter E. Huber, Antoine Italiano, Sana D. Karam, Guido Kroemer, Philippe Lambin, Carola Leuschner, Alberto Mantovani, Etienne Meylan, Michele Mondini, Mikael J. Pittet, Jean-Pierre Pouget, Jordi Remon, Claus S. Sørensen, Christos Sotiriou, Claire Vanpouille-Box, Ralph R. Weichselbaum, James W. Welsh, Laurence Zitvogel, Silvia C. Formenti, Eric Deutsch

    Published 2025-12-01
    Get full text
    Article
    Save to List
    Saved in:

Search Tools: